SCYX SCYNEXIS Inc.

0.49
-0.03  -6%
Previous Close 0.52
Open 0.52
Price To Book 0.84
Market Cap 23506120
Shares 47,971,673
Volume 455,411
Short Ratio
Av. Daily Volume 340,855

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181175418
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 181139439
  3. 8-K - Current report 181081637
  4. EFFECT - Notice of Effectiveness 181072286
  5. 424B3 - Prospectus [Rule 424(b)(3)] 181071907

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing of first patient announced October 15, 2018.
SCY-078 - oral - CARES
Candida Auris
Phase 2 trial initiated 3Q 2018.
Ibrexafungerp (SCY-078)
Invasive aspergillosis
Phase 2 trial to be initiated 2H 2018.
Intravenous SCY-078
Invasive candidiasis
Phase 3 trial to be initiated 4Q 2018.
SCY-078 - oral
Vulvovaginal candidiasis (VVC)
Phase 3 open label trial commenced 3Q 2017. Preliminary data review 4Q 2018.
SCY-078 - oral (FURI)
Invasive candidiasis

Latest News

  1. Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018
  2. SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
  3. Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
  4. Scynexis: 3Q Earnings Snapshot
  5. SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
  6. SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
  7. SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
  8. SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
  9. SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
  10. Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
  11. 5 Healthcare Stocks That Are Down, But Not Out!
  12. SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
  13. Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates
  14. SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
  15. Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
  16. The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
  17. Why Scynexis Stock Rose 16.4% Yesterday
  18. SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181175418
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 181139439
  3. 8-K - Current report 181081637
  4. EFFECT - Notice of Effectiveness 181072286
  5. 424B3 - Prospectus [Rule 424(b)(3)] 181071907
  6. 424B5 - Prospectus [Rule 424(b)(5)] 181071889
  7. CORRESP [Cover] - Correspondence
  8. UPLOAD [Cover] - SEC-generated letter
  9. S-3 - Registration statement under Securities Act of 1933 181050584
  10. 8-K - Current report 181005987